Lebrikizumab for Atopic Dermatitis Affecting the Face and Neck
Tests lebrikizumab against placebo in teens and adults with face and neck eczema.
Plain-language title generated from the registry record
Registry title: A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
Key facts
- Where
- Gdansk, Rzeszów, Warsaw, and Wroclaw, PolandSee the 4 sites
- Phase
- Phase 3
Where in Poland
- Uniwersyteckie Centrum KliniczneGdansk, PolandNot yet recruiting
- Uniwersytecki Szpital Kliniczny Im. Fryderyka Chopina W RzeszowieRzeszów, PolandNot yet recruiting
- Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyWarsaw, PolandNot yet recruiting
- Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.pWroclaw, PolandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Almirall, S.A.
- Trial code
- NCT07873801EU 2025-525133-31-00
- Record updated
- 14 October 2026
- Original description
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD outside of the face and neck region, and who are in need of systemic therapy.Read full original descriptionShow less
A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD outside of the face and neck region, and who are in need of systemic therapy.
Inclusion: Participants eligible for inclusion in this trial must fulfil all of the following criteria:; Adults and adolescents (aged [greater than or equal to (>=)] 12 years to [less than (<)]18 years at the time of informed consent form [ICF]/informed assent form [IAF] signature and weighing >=40 kilograms [kg]) who are candidates for AD systemic therapy; Chronic AD (according to Hanifin and Rajka Criteria (Hanifin 1980)) that has been present for >=1 year before the Screening visit; At least moderate FNAD with F-IGA >=3 (scale of 0 [clear] to 4 [severe]) at Screening and Day 1/Baseline; Overall EASI score >=12 at Day 1/Baseline with distinct atopic dermatitis lesions in at least one area outside the face and neck.
Exclusion: Prior treatment with lebrikizumab; Prior treatment at any time with more than one of the following advanced systemic treatments: Dupilumab, tralokinumab, nemolizumab, or oral JAK inhibitors; Intention to use any concomitant medication or therapy that is not permitted by this protocol or failure to undergo the required washout period for a particular prohibited medication; Presence of dermatological conditions and/or skin signs or symptoms on the face and/or neck that may interfere with study assessments including but not limited to rosacea, flushing, demodicosis, and seborrheic dermatitis; History of human immunodeficiency virus (HIV) infection (including known positive HIV serology in medical history); Uncontrolled chronic disease that might require use of systemic corticosteroids, eg, uncontrolled asthma; Known liver cirrhosis and/or chronic hepatitis of any aetiology and/or current infection (at Screening) with hepatitis B or hepatitis C; History of malignancy, including mycosis fungoides, within 5 years before the Screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks; Participants fulfilling any of the following criteria are not eligible for inclusion in this trial:; Participants with suspected clinically relevant contact dermatitis of the face and neck region, and participants with a confirmed contact allergen known to exacerbate their atopic dermatitis who cannot commit to allergen avoidance or when allergen avoidance is not possible; Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.